MDS Abstracts

Abstracts from the International Congress of Parkinson’s and Movement Disorders.

MENU 
  • Home
  • Meetings Archive
    • 2024 International Congress
    • 2023 International Congress
    • 2022 International Congress
    • MDS Virtual Congress 2021
    • MDS Virtual Congress 2020
    • 2019 International Congress
    • 2018 International Congress
    • 2017 International Congress
    • 2016 International Congress
  • Keyword Index
  • Resources
  • Advanced Search

Articles tagged "Botulinum toxin: Clinical applications: spasticity"

  • MDS Virtual Congress 2021

    Improvement of spasticity-related pain with incobotulinumtoxinA treatment in children/adolescents with cerebral palsy: pooled analysis of Phase 3 studies

    F. Heinen, P. Kaňovský, A. Schroeder, H. Chambers, E. Dabrowski, T. Geister, A. Hanschmann, I. Pulte, M. Althaus, M. Banach, D. Gaebler-Spira (Munich, Germany)

    Objective: To assess the effect of incobotulinumtoxinA on spasticity-related pain (SRP) using pooled data from three large Phase 3 pediatric studies. Background: In children/adolescents with…
  • MDS Virtual Congress 2020

    Efficacy and Safety of IncobotulinumtoxinA in the Treatment of Lower Limb Spasticity in Japanese Subjects

    Y. Masakado, A. Dekundy, A. Hanschmann, R. Kaji (Kanagawa, Japan)

    Objective: To confirm the efficacy and safety of incobotulinumtoxinA (INCO; Xeomin®, Merz Pharmaceuticals GmbH) in East Asian subjects from study sites in Japan with post-stroke…
  • MDS Virtual Congress 2020

    Pregnancy Outcomes Following Exposure to OnabotulinumtoxinA Update – 29 Years of Safety Observation

    M. Brin, A. Adams, L. Parker, A. Ukah, L. Radulian, L. Yedigarova, I. Yushmanova (Irvine, CA, USA)

    Objective: The present study evaluated pregnancy outcomes following onabotulinumtoxinA exposure to provide a cumulative 29-year safety update. Background: A previous publication of pregnancy outcomes in…
  • MDS Virtual Congress 2020

    Management of Cervical Dystonia & Spastic Paresis with Botulinum Neurotoxin-A: results from the INPUT survey

    R. Bhidayasiri, L.J Jacinto, K. Bhatia, N. Dursun, T.M Chung, J. Tiley, C. Colosimo (Bangkok, Thailand)

    Objective: To describe current practices among physicians using botulinum toxin-A (BoNT-A) to treat spastic paresis (SP) and cervical dystonia (CD). Background: BoNT-A is an effective…
  • MDS Virtual Congress 2020

    Multi-level and multi-pattern lower- and upper-limb spasticity treatment with incobotulinumtoxinA in children and adolescents with cerebral palsy

    E. Dabrowski, H. Chambers, F. Heinen, P. Kaňovský, S. Schroeder, M. Banach, H. Dersch, T. Geister, F. Martinez-Torres, I. Pulte, D. Gaebler-Spira (Royal Oak, MI, USA)

    Objective: Assess efficacy and safety of incobotulinumtoxinA in lower-limb (LL) or combined LL/upper-limb (LL/UL) spasticity in children and adolescents with cerebral palsy (CP). Background: Ambulant…
  • MDS Virtual Congress 2020

    Phenotyping spasticity-associated tonic spasms: implications for therapy

    H. Abboud, S. Saad, M. Elkasaby, C. Kilbane (Cleveland, OH, USA)

    Objective: To evaluate common phenotypes of tonic spasms (TS) in patients with spasticity and inform therapeutic interventions. Background: Spasticity can be associated with several hyperkinetic…
  • MDS Virtual Congress 2020

    Treatment with Botulinum Toxin for Refractory Fever caused by Severe Spasticity

    J. Lester, G. Alvarez-Resendiz, E. Klériga, F. Videgaray, G. Zambito (Huixquilucan, Mexico)

    Objective: Present a series of cases of patients with refractory fever associated to spasticity secondary to a brain or spinal cord injury who developed refractory…
  • MDS Virtual Congress 2020

    Identification of Factors that Impact Adherence to OnabotulinumtoxinA Treatment for Spasticity in Post-Stroke and Multiple Sclerosis Patients from ASPIRE

    A. Esquenazi, W. Feng, G. Wittenberg, P. Gallien, A. Baricich, K. Fanning, A. Zuzek, G. Francisco, D. Bandari (Elkins Park, PA, USA)

    Objective: Identify baseline clinical characteristics and treatment-related factors that impact adherence to onabotulinumtoxinA (onabotA) treatment in post-stroke and multiple sclerosis (MS) patients from the Adult…
  • MDS Virtual Congress 2020

    Perceptions of burden of spasticity and treatment satisfaction among post-stroke patients over the course of a botulinum neurotoxin A (BoNT-A) treatment cycle: An ethnographic study

    J. Jacinto, A. Lysandropoulos, A. Fulford-Smith (Estoril, Portugal)

    Objective: To design an ethnographic study following patients over a botulinum toxin type-A (BoNT-A) treatment cycle to inform individualized treatment. Background: The concept of individualized…
  • 2019 International Congress

    OnabotulinumtoxinA Reduces Disability in Treatment-Naive Adult Patients with Spasticity: Results from the ASPIRE Study

    W. Jost, A. Ellenbogen, G. Wittenberg, K. Ngo, J. Largent, A. Zuzek, G. Francisco, A. Esquenazi (Irvine, CA, USA)

    Objective: Examine real-world onabotulinumtoxinA utilization and effectiveness over 2 years in patients naive or non-naive to botulinum toxins for spasticity from the Adult Spasticity International…
  • « Previous Page
  • 1
  • 2
  • 3
  • 4
  • 5
  • 6
  • 7
  • Next Page »

Most Viewed Abstracts

  • This Week
  • This Month
  • All Time
  • Covid vaccine induced parkinsonism and cognitive dysfunction
  • Life expectancy with and without Parkinson’s disease in the general population
  • What is the appropriate sleep position for Parkinson's disease patients with orthostatic hypotension in the morning?
  • Patients with Essential Tremor Live Longer than their Relatives
  • Increased Risks of Botulinum Toxin Injection in Patients with Hypermobility Ehlers Danlos Syndrome: A Case Series
  • Covid vaccine induced parkinsonism and cognitive dysfunction
  • What is the appropriate sleep position for Parkinson's disease patients with orthostatic hypotension in the morning?
  • Life expectancy with and without Parkinson’s disease in the general population
  • The hardest symptoms that bother patients with Parkinson's disease
  • An Apparent Cluster of Parkinson's Disease (PD) in a Golf Community
  • Effect of marijuana on Essential Tremor: A case report
  • Increased Risks of Botulinum Toxin Injection in Patients with Hypermobility Ehlers Danlos Syndrome: A Case Series
  • Covid vaccine induced parkinsonism and cognitive dysfunction
  • Estimation of the 2020 Global Population of Parkinson’s Disease (PD)
  • Patients with Essential Tremor Live Longer than their Relatives
  • Help & Support
  • About Us
  • Cookies & Privacy
  • Wiley Job Network
  • Terms & Conditions
  • Advertisers & Agents
Copyright © 2025 International Parkinson and Movement Disorder Society. All Rights Reserved.
Wiley